Key clinical point: Eptinezumab vs placebo led to a greater reduction in migraine frequency and an improvement in migraine response in patients with migraine, irrespective of the type of prior treatment failure.
Major finding: Across weeks 1-12, patients receiving eptinezumab vs placebo experienced greater reductions in monthly migraine days (MMD) from baseline in all subgroups, with even greater improvements at weeks 13-24 (all P < .0001). Migraine responder rates ( ≥50% reduction in MMD) were also higher with eptinezumab vs placebo and increased following a second infusion (all P < .0001).
Study details: Findings are from a post hoc analysis of the DELIVER trial that included 890 patients with migraine who were randomly assigned to receive either 100 mg or 300 mg eptinezumab or placebo.
Disclosures: The study was sponsored and funded by H. Lundbeck A/S. Several authors declared receiving personal fees, research support, or research funding from various sources. Four authors declared being full-time employees of or holding stocks in Lundbeck or one of its subsidiary companies.
Source: Pozo-Rosich P, Ashina M, Tepper SJ et al. Eptinezumab demonstrated efficacy regardless of prior preventive migraine treatment failure type: Post hoc analyses of the DELIVER study. Neurol Ther. 2024 (Jan 18). doi: 10.1007/s40120-023-00575-5 Source